KN38-7271/BAY38-7271 – synthetic, CB1 & CB2 agonist


Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4- oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.        (full – 2002)


BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.                                                     (abst – 2003)


Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271.                                                         (abst – 2003)


Breakthrough in treatment of Traumatic Brain Injury: KeyNeurotek’s clinical study reaches primary endpoint and shows significant increase in survival                                                                       (news – 2009)







Early Survival of Comatose Patients after Severe Traumatic Brain Injury with the Dual Cannabinoid CB1/CB2 Receptor Agonist KN38-7271: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.           (abst – 2012)


Cannabinoid Receptor Subtypes 1 and 2 Mediate Long-Lasting Neuroprotection and Improve Motor Behaviour Deficits After Transient Focal Cerebral Ischemia.

(abst – 2012)            

Share a link for